Bio & Pharma
Celltrion to acquire additional $72 mn in treasury shares
From November 22, the company's 583,431 shares will be repurchased on the market, bringing the total to $308 mn
By Nov 21, 2024 (Gmt+09:00)
1
Min read
Most Read
LG Chem to sell water filter business to Glenwood PE for $692 million


Kyobo Life poised to buy Japan’s SBI Group-owned savings bank


KT&G eyes overseas M&A after rejecting activist fund's offer


StockX in merger talks with Naver’s online reseller Kream


Mirae Asset to be named Korea Post’s core real estate fund operator



South Korea's Celltrion Inc. announced on Thursday that it decided to repurchase additional treasury shares worth 100 billion won ($71.6 million).
From November 22, Celltrion plans to acquire 583,431 treasury shares through on-market purchases.
The company stated that this additional buyback is part of a shareholder-friendly policy to prioritize and enhance shareholder value.
The decision was made in response to the company's judgment that its corporate valuation has slowed, despite achieving record-breaking third-quarter sales and ongoing growth of its flagship products in global markets, along with approvals for new products.
Previously, Celltrion projected that its revenue for this year would reach a record high of 3.5 trillion won ($2.5 billion).
This marks the fifth share buyback by Celltrion this year, bringing the cumulative total for 2024 to 2,394,031 shares worth 430 billion won ($307.7 million).
Celltrion has consistently pursued shareholder value enhancement policies, including repurchasing 1,239 billion won ($886.5 million) worth of treasury shares last year.
This year, the company has also combined share buybacks with the cancellation of 700 billion won ($500.9 million) worth of treasury shares.
Write to Dae-Kyu Ahn at powerzanic@hankyung.com
More to Read
-
Bio & PharmaCelltrion acquires Swiss pharmaceutical distributor iQone
Nov 15, 2024 (Gmt+09:00)
1 Min read -
-
Bio & PharmaCelltrion's Zymfentra gets 90% distribution channel in US
Oct 30, 2024 (Gmt+09:00)
1 Min read -
-
Bio & PharmaCelltrion's anti cancer drugs hold 90% market share in C.America
Oct 11, 2024 (Gmt+09:00)
1 Min read
Comment 0
LOG IN